How do I obtain ANVISA, COFEPRIS, ANMAT, or Panama MINSA approval for a medical device clinical trial?
Each regulator pairs an ethics-committee review with a national health-authority authorization. In practice: Panama (MINSA, ethics-driven via CNBI) is typically fastest at ~2–4 months; Mexico (COFEPRIS) ~3–8 months; Brazil (ANVISA + CEP/CONEP) ~6–12 months; Argentina (ANMAT) varies by device risk class. All four accept the same core dossier — protocol, Investigator's Brochure, informed consent, trial insurance, and device technical file. bioaccess® manages the full submission in each country.
Country crosswalk: ANVISA vs COFEPRIS vs ANMAT vs MINSA
Ranges are experience-based typical values and vary by device class and dossier completeness.
- Panama — MINSA (Ministerio de Salud, via the Dirección Nacional de Farmacia y Drogas). Ethics review by institutional bioethics committees registered with the CNBI. Trial authorization typically ~2–4 months; ethics ~3–6 weeks. Ethics-committee-driven pathway — for many early-feasibility and first-in-human device studies the EC is the primary decision-maker. Typically the fastest LATAM route.
- Mexico — COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios). Ethics via COFEPRIS-registered ethics (CEI) and research committees. Trial authorization typically ~3–8 months; ethics ~4–8 weeks. Requires a Mexican legal representative; review runs in parallel with ethics approval.
- Brazil — ANVISA (Agência Nacional de Vigilância Sanitária). Ethics via CEP (local committee) with CONEP national oversight for applicable studies. Trial authorization typically ~6–12 months; ethics ~8–16 weeks. The most document-intensive of the four; requires a Brazilian sponsor/representative.
- Argentina — ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica). Ethics via jurisdictional/institutional committees, reviewed in parallel with ANMAT. Timeline varies by device risk category; requires a local authorized representative.
Documents all four regulators require
- Clinical investigation protocol (device description, risk analysis, endpoints, statistics)
- Investigator's Brochure / device technical file with preclinical and bench evidence
- Informed consent form(s) in the local language
- Clinical trial insurance / subject indemnity certificate
- Investigator CVs, site qualifications, and delegation logs
- Import permit / authorization for the investigational device
- Local sponsor or authorized representative of record (required in Brazil, Mexico, Argentina)
Frequently asked questions
Do I need both ethics-committee and health-authority approval in Latin America?
In almost all cases, yes. Every country here pairs an independent ethics-committee (IRB/CEI/CEP) review with a national health-authority authorization. Panama is the most ethics-committee-driven — for many first-in-human device studies the registered bioethics committee, under CNBI oversight, is the primary decision-maker — while Brazil (ANVISA + CEP/CONEP), Mexico (COFEPRIS), and Argentina (ANMAT) run both tracks, sometimes in parallel.
Which of these regulators is fastest for a first-in-human device study?
In bioaccess®' experience, Panama's ethics-committee-driven pathway (MINSA/CNBI) is typically the fastest route to a first-in-human device study, with authorization often in ~2–4 months. Mexico (COFEPRIS) is usually next, then Brazil (ANVISA), which is the most document-intensive. Argentina (ANMAT) varies by device risk class. Actual timelines depend on device class, dossier completeness, and ethics-committee calendars.
Will the FDA accept data from a device trial run under ANVISA, COFEPRIS, ANMAT, or MINSA?
Yes, when the study is designed for it. Under 21 CFR 812.28, the FDA accepts data from investigations conducted outside the US to support an IDE, 510(k), De Novo, or PMA when the study meets ISO 14155 Good Clinical Practice and the FDA can validate the data. bioaccess® designs Latin American device studies around a U.S. regulatory anchor (typically an FDA Pre-Submission) so the resulting data supports the intended U.S. pathway.
Does bioaccess® handle the submissions in each country?
Yes. bioaccess® manages the end-to-end regulatory submission and ethics-committee process in each country — dossier assembly, translations, sponsor/authorized-representative of record where required, ethics-committee and health-authority filing, and investigational-device import — as part of its first-in-human program.
Related resources